Celyad-Logo-Color.jpg
Celyad Oncology announces intention to terminate SEC reporting obligations
08 févr. 2024 16h01 HE | Celyad Oncology SA
MONT-SAINT-GUIBERT, Belgium, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext: CYAD) (“Celyad Oncology” or the “Company”) announces that it will voluntarily file a Form 15F with the...
Celyad-Logo-Color.jpg
Celyad Oncology provides fourth quarter 2023 business update and 2024 outlook
16 janv. 2024 16h01 HE | Celyad Oncology SA
Three main pillars to unlock the potential of proprietary technology platforms and intellectual property: A proprietary non-gene editing technology platform based on multiplexing of short hairpin...
Celyad-Logo-Color.jpg
Publication of a transparency notification received from Fortress Investment Group LLC (Article 14 §1 of the Law of 2 May 2007)
20 déc. 2023 16h01 HE | Celyad Oncology SA
MONT-SAINT-GUIBERT, Belgium, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext: CYAD) (“Celyad Oncology” or the “Company”) today announces, in accordance with Article 14 of the Belgian...
Celyad-Logo-Color.jpg
Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)
15 déc. 2023 16h01 HE | Celyad Oncology SA
MONT-SAINT-GUIBERT, Belgium, Dec. 15, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology (Euronext: CYAD) (the “Company” or “Celyad Oncology”), today announces that 6,500,000 shares of CFIP CLYD (UK) Limited...
Celyad-Logo-Color.jpg
Celyad announces management change
04 déc. 2023 16h01 HE | Celyad Oncology SA
MONT-SAINT-GUIBERT, Belgium, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology (Euronext: CYAD), a cutting-edge biotechnology company dedicated to pioneering the discovery and advancement of...
Celyad-Logo-Color.jpg
Publication of a transparency notification received from Tolefi SA (Article 14 §1 of the Law of 2 May 2007)
01 déc. 2023 06h42 HE | Celyad Oncology SA
MONT-SAINT-GUIBERT, Belgium, Dec. 01, 2023 (GLOBE NEWSWIRE) -- regulated information – Celyad Oncology SA (Euronext: CYAD) (“Celyad Oncology” or the “Company”) today announced, in accordance with...
Celyad-Logo-Color.jpg
Publication of a transparency notification received from Fortress Investment Group LLC (Article 14 §1 of the Law of 2 May 2007)
21 nov. 2023 16h00 HE | Celyad Oncology SA
MONT-SAINT-GUIBERT, Belgium, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext: CYAD) (“Celyad Oncology” or the “Company”) today announced, in accordance with Article 14 of the Belgian...
Celyad-Logo-Color.jpg
Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)
14 nov. 2023 16h00 HE | Celyad Oncology SA
MONT-SAINT-GUIBERT, Belgium, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology (Euronext: CYAD) (the “Company” or “Celyad Oncology”), today announces the below information following the issuance, on...
Celyad-Logo-Color.jpg
Celyad Oncology reports third quarter 2023 financial results and recent business highlights
09 nov. 2023 01h00 HE | Celyad Oncology SA
Publication of data detailing the development of our microRNA (miRNA)-based multiplex shRNA approach, which allows to down-regulate several genes simultaneously, in Molecular Therapy – Nucleic...
Celyad-Logo-Color.jpg
Celyad Oncology announces the termination of its American Depository Receipt program
25 sept. 2023 16h01 HE | Celyad Oncology SA
MONT-SAINT-GUIBERT, Belgium, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext: CYAD) (“Celyad Oncology” or the “Company”) today announces that Citibank, N.A., as depositary...